
402 ‒ NMR blood analysis: how mortality risk and more can be assessed from a single blood sample
In this episode of the Drive Podcast, Peter Attia talks with Jim Otvos, the inventor of NMR-based lipoprotein analysis (LDL-P, HDL-P). The conversation covers the technology's origins, its clinical significance, and the current state of research.
The Beginnings: NMR and Serendipity
- Jim Otvos initially used NMR to study biomolecular structures.
- A highly publicized New England Journal paper claimed that NMR could detect cancer with a simple signal.
- Otvos showed that the signal actually came from lipoproteins – not cancer – laying the groundwork for a new diagnostic approach.
- Key discovery: VLDL, LDL, and HDL produce distinct NMR signals, from which concentrations and particle sizes can be derived.
LDL Particle Number vs. LDL Cholesterol
- LDL-P (particle number) is a better risk marker than LDL-C (cholesterol) because cholesterol is transported within particles.
- The discordance between LDL-C and LDL-P explains why some people with low LDL-C still have elevated risk: particle count can be high while cholesterol is low.
- At a given LDL-P, particle size (small-dense vs. large-buoyant) is not independently associated with risk. What matters is the number of particles, not their size.
ApoB and Other Biomarkers
- ApoB is an alternative marker reflecting the number of atherogenic particles.
- Otvos emphasizes that LDL-P and ApoB are largely equivalent and both superior to LDL-C for risk assessment.
LPIR and Diabetes Risk
- The LPIR score (Lipoprotein Insulin Resistance Index) combines six lipoprotein subclasses into a measure of insulin resistance.
- It is a strong predictor of developing type 2 diabetes and can signal metabolic issues long before blood glucose rises.
- The Diabetes Risk Index (DRI) additionally incorporates branched-chain amino acids.
GlycA: An Inflammatory Marker
- GlycA is an NMR-based marker of systemic inflammation, derived from glycans on acute-phase proteins.
- It is more stable than CRP and independently associated with mortality.
MVX: Metabolic Vulnerability Index
- The MVX score combines six parameters: small HDL-P, GlycA, citrate, and the branched-chain amino acids leucine, isoleucine, and valine.
- It strongly predicts all-cause mortality – even in apparently healthy individuals, including 30-year-olds.
- The association is independent of existing diseases and indicates a metabolic vulnerability that increases the risk of death.
- MVX is not only a diagnostic marker but could also be used for risk stratification in clinical trials and therapeutic decisions.
Commercial Challenges
- Otvos founded Liposcience to bring NMR technology into clinical practice.
- The acquisition by LabCorp halted the vision of broad IVD distribution.
- Only a few Vanta analyzers exist today, and they are aging. A new IVD company would be needed to preserve and further develop the technology.
Conclusion
NMR-based tests provide a wealth of information from a single blood sample – from lipids to inflammation to metabolic and mortality risk. The technology is analytically efficient and inexpensive, but commercially difficult to establish in the US. Otvos hopes for a revival through a new company that leverages the existing infrastructure and patents.






